Investigation of Ferritin in Critically Ill Patients With Hemophagocytic Lymphohistiocytosis

NCT02854943 | Completed

• 1 other identifier: HLH
• Study Type: observational
• Target: 2,623
• Locations: 0 countries
• Sites: N/A

Brief Summary

Retrospective analysis of ferritin, outcome and HLH-criteria in critically ill patients.

Conditions

Hemophagocytic Lymphohistiocytosis (HLH); Macrophage Activation Syndrome (MAS); Hemophagocytic Syndromes

Keywords

Ferritin; Hemophagocytic lymphohistiocytosis (HLH); Critically ill patients; intensive care unit (ICU); Outcome; Diagnosis

Outcome Measures

Primary Outcomes (2)

• Mortality

  A retrospective analysis of patients with available charts to determine the outcome whether patients survived the ICU or died.

  Participants will be followed up for the duration of hospital stay, an expected average of two months

• Probability of having undiagnosed Hemophagocytic lymphohistiocytosis (HLH)

  Retrospective analysis of available charts, underlying diagnoses, findings and blood values: HLH-2004 criteria (Henter JI et al. 2007) and HScore (Fardet L et al. 2014)

  The participants will be followed up for the duration of hospital stay, an expected average of two months

Secondary Outcomes (3)

• Diagnoses

  Participants will be followed up for the duration of hospital stay, an expected average of two months

• Intensive care unit stay

  Participants will be followed up for the duration of intensive care unit stay, an expected average of one week

• Improving HLH diagnostic criteria including multicenter validation

  Participants will be followed up for the duration of intensive care unit stay, an expected average of one week

Study Arms (1)

Critically ill patients

Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Male and female critically ill patients admitted to the Charité - Universitätsmedizin Berlin during 2000 and 2018

You may qualify if:

• male and female patients
• at least one measurement of plasma ferritin

You may not qualify if:

• age below 18 years

Sponsors & Collaborators

• Gunnar Lachmann: lead

Related Publications (6)

• Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31. doi: 10.1002/pbc.21039.

  PMID: 16937360 BACKGROUND

• Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014 Sep;66(9):2613-20. doi: 10.1002/art.38690.

  PMID: 24782338 BACKGROUND

• Knaak C, Schuster FS, Nyvlt P, Heeren P, Spies C, Schenk T, La Rosee P, Janka G, Brunkhorst FM, Lachmann G. Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients. PLoS One. 2021 Jul 12;16(7):e0254345. doi: 10.1371/journal.pone.0254345. eCollection 2021.

  PMID: 34252125 DERIVED

• Knaak C, Nyvlt P, Schuster FS, Spies C, Heeren P, Schenk T, Balzer F, La Rosee P, Janka G, Brunkhorst FM, Keh D, Lachmann G. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care. 2020 May 24;24(1):244. doi: 10.1186/s13054-020-02941-3.

  PMID: 32448380 DERIVED

• Knaak C, Schuster FS, Spies C, Vorderwulbecke G, Nyvlt P, Schenk T, Balzer F, La Rosee P, Janka G, Brunkhorst FM, Keh D, Lachmann G. Hemophagocytic Lymphohistiocytosis in Critically Ill Patients. Shock. 2020 Jun;53(6):701-709. doi: 10.1097/SHK.0000000000001454.

  PMID: 31626037 DERIVED

• Lachmann G, Spies C, Schenk T, Brunkhorst FM, Balzer F, La Rosee P. Hemophagocytic Lymphohistiocytosis: Potentially Underdiagnosed in Intensive Care Units. Shock. 2018 Aug;50(2):149-155. doi: 10.1097/SHK.0000000000001048.

  PMID: 30010630 DERIVED

MeSH Terms

Conditions

Lymphohistiocytosis, Hemophagocytic; Macrophage Activation Syndrome; Disease

Condition Hierarchy (Ancestors)

Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Lymphatic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Gunnar Lachmann, MD

  Charité - Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine

  STUDY DIRECTOR

• Gunnar Lachmann, MD

  Charité - Universitätsmedizin Berlin, Department of Anesthesiology and Operative Intensive Care Medicine

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Specialist in Anesthesiology of the Department of Anesthesiology and Intensive Care Medicine CVK/CCM

Study Record Dates

• First Submitted: August 1, 2016
• First Posted: August 4, 2016
• Study Start: January 1, 2000
• Primary Completion: August 1, 2018
• Study Completion: August 1, 2018
• Last Updated: December 7, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share